HIGH LEVELS OF CIRCULATING PLASMA CELLS ARE AN INDEPENDENT HIGH-RISK FEATURE IN MULTIPLE MYELOMA PATIENTS AND THEIR PROGNOSTIC IMPACT IS MODULATED BY THE ACHIEVEMENT OF MINIMAL RESIDUAL DISEASE NEGATIVITY

被引:0
|
作者
Bertamini, L. [1 ]
Stefanoni, P. [1 ]
Tacchetti, P. [1 ]
Ledda, A. [1 ]
Palmas, A. [1 ]
Gentile, M. [1 ]
Palmieri, S. [1 ]
Annibali, O. [1 ]
Musolino, C. [1 ]
Burdisso, M. [1 ]
Capra, A. [1 ]
Rizzi, R. [1 ]
Molica, S. [1 ]
Cellini, C. [1 ]
Monaco, F. [1 ]
De Sabbata, G. [1 ]
Cea, M. [1 ]
Rivolti, E. [1 ]
Fazio, F. [1 ]
Musto, P. [1 ]
Boccadoro, M. [1 ]
Gay, F. [1 ]
机构
[1] European Myeloma Network, Turin, Italy
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
C008
引用
收藏
页码:12 / 13
页数:2
相关论文
共 50 条
  • [21] Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China
    Mei, Jiangang
    Zhai, Yongping
    Li, Hanqing
    Li, Feng
    Zhou, Xiaogang
    Song, Ping
    Zhao, Qian
    Yu, Yaping
    An, Zhiming
    Wang, Liping
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (11) : 2263 - 2273
  • [22] Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China
    Jiangang Mei
    Yongping Zhai
    Hanqing Li
    Feng Li
    Xiaogang Zhou
    Ping Song
    Qian Zhao
    Yaping Yu
    Zhiming An
    Liping Wang
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 2263 - 2273
  • [23] Treatment options for multiple myeloma patients with high-risk disease
    Ailawadhi, Sikander
    Masood, Aisha
    Sher, Taimur
    Miller, Kena C.
    Wood, Margaret
    Lee, Kelvin
    Chanan-Khan, Asher
    MEDICAL ONCOLOGY, 2010, 27 : 53 - 61
  • [24] Treatment options for multiple myeloma patients with high-risk disease
    Sikander Ailawadhi
    Aisha Masood
    Taimur Sher
    Kena C. Miller
    Margaret Wood
    Kelvin Lee
    Asher Chanan-Khan
    Medical Oncology, 2010, 27 : 53 - 61
  • [25] Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
    Nahi, Hareth
    Afram, Gabriel
    Uttervall, Katarina
    Lockmer, Sandra
    Tatting, Love
    Gahrton, Gosta
    Kashif, Muhammad
    Alici, Evren
    Stromberg, Olga
    Klimkowska, Monika
    Lund, Johan
    CANCER MEDICINE, 2023, 12 (22): : 20736 - 20744
  • [26] A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma
    Muz, Barbara
    de la Puente, Pilar
    Azab, Feda
    Luderer, Micah John
    King, Justin
    Vij, Ravi
    Azab, Abdel Kareem
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (01) : 70 - 81
  • [27] Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma
    Mocellin, S
    Del Fiore, P
    Guarnieri, L
    Scalerta, R
    Foletto, M
    Chiarion, V
    Pilati, P
    Nitti, D
    Lise, M
    Rossi, CR
    INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (05) : 741 - 745
  • [28] Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
    Kumar, Shaji
    Fonseca, Rafael
    Ketterling, Rhett P.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dingli, David
    Knudson, Ryan A.
    Greenberg, Alexandra
    Russell, Stephen J.
    Zeldenrust, Steven R.
    Lust, John A.
    Kyle, Robert A.
    Bergsagel, Leif
    Rajkumar, S. Vincent
    BLOOD, 2012, 119 (09) : 2100 - 2105
  • [29] Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition
    Granell, Miquel
    Calvo, Xavier
    Garcia-Guinon, Antoni
    Escoda, Lourdes
    Abella, Eugenia
    Ma Martinez, Clara
    Teixido, Montserrat
    Teresa Gimenez, Ma
    Senin, Alicia
    Sanz, Patricia
    Campoy, Desiree
    Vicent, Ana
    Arenillas, Leonor
    Rosinol, Laura
    Sierra, Jorge
    Blade, Joan
    Fernandez de Larrea, Carlos
    HAEMATOLOGICA, 2017, 102 (06) : 1099 - 1104
  • [30] Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)
    Guerrero, Camila
    Termini, Rosalinda
    Garces, Juan-Jose
    Jose Calasanz, Maria
    Rios, Rafael
    Cabezudo, Elena
    Rosinol, Laura
    Joan, Bargay
    Perez-Montana, Albert
    Oriol Rocafiguera, Albert
    Cabanas Perianes, Valentin
    Najera, Maria-Josefa
    Garcia, Esther Gonzalez
    Ocio, Enrique M.
    Sureda Balari, Anna Maria
    De Arriba, Felipe
    Hernandez Garcia, Miguel Teodoro
    Garcia, Antonio
    Martinez-Lopez, Joaquin
    Blanchard, Maria-Jesus
    Gonzalez Perez, Marta Sonia
    Iglesias, Rebeca
    Orfao, Alberto
    Victoria Mateos, Maria
    Lahuerta Palacios, Juan Jose
    Blade, Joan
    San-Miguel, Jesus
    Cedena, Maria T.
    Puig, Noemi
    Paiva, Bruno
    BLOOD, 2023, 142